Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Ophthalmic Plast Reconstr Surg. 2020 Sep-Oct;36(5):444–450. doi: 10.1097/IOP.0000000000001585

TABLE 1.

Expression of PD-L1 and PD-L2, and CD8 T-lymphocyte infiltration

Marker Degree of expression (mean ± standard deviation); n = 23 samples
PD-L1 overall* 1.4 ± 0.9 (n = 23); expression was 0 in 2 samples
 PD-L1 tumor 0.73 ± 1.1
 PD-L1 stroma 1.1 ± 1.1
 PD-L1 endothelium 0.96 ± 1.1
PD-L2 overall 0.83 ± 1.1 (n = 23); expression was 0 in 4 samples
 PD-L2 tumor 0.22 ± 0.85
 PD-L2 stroma 0.87 ± 1.2
 PD-L2 endothelium 0.04 ± 0.21
CD8 overall 1.1 ± 0.51 (n = 23); expression was 0 in 2 samples
 CD8 tumor 0.39 ± 0.5
 CD8 stroma 1.3 ± 0.62
Combined positive score Degree of expression (mean ± standard deviation); n = 23 samples
PD-L1 ≥ 1 57% (n = 13 samples)
PD-L1 < 1 43% (n = 10 samples)
*

PD-L1 scored on a 0–5 scale.

PD-L2 scored on a 0–5 scale.

CD8 scored on a 0–3 scale.

PD-L, programmed celi death ligand.